Siamab’s ST1 Therapy Candidate Promising Against Chemoresistant Ovarian Cancer, Study Shows
News
Siamab Therapeutics‘ investigational antibody-drug conjugate ST1 has promising anti-tumor effects against chemotherapy-resistant ovarian cancer in cell and animal models, a study shows. The study, “Treatment of ovarian cancer by targeting the tumor stem cell-associated ... Read more